#409 Less than 140, 130, or 120? Counting down to the optimal systolic blood pressure target.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
- At least 5 systematic reviews in past 5 years.1-6 All results statistically significant unless stated.
- Focusing on individual participant-level meta-analysis of 6 largest, randomized controlled trials (RCTs) with 80,676 participants (average age 64, 44% with 10-year cardiovascular risk ≥20%) comparing “intensive” (<120-130) versus “standard” (<140-150) SBP target.1
- At 3.2 years:
- Cardiovascular death: 1.1% versus 1.5% (standard), number needed to treat (NNT)=250.
- All-cause death reduced, but event rates not reported.
- Cardiovascular events: 5.3% versus 7.1% (standard), NNT=59.
- Side-effects: 7.2% versus 5.4% (standard), number needed to harm (NNH)=56.
- Examples:2 Hypotension (NNH=~500), acute kidney injury (NNH=~1600), syncope (NNH=~1700), injurious falls (NNH=~2900), electrolyte abnormality (NNH=~3200).
- Intensive group required 0.5-2 additional BP medications.
- Cardiovascular death: 1.1% versus 1.5% (standard), number needed to treat (NNT)=250.
- Similar NNT for cardiovascular events in RCTs targeting SBP <120 mmHg (NNT=56) and <130 mmHg (NNT=61).
- Similar efficacy and safety in patients with or without diabetes or stroke history.
- At 3.2 years:
- Other systematic reviews with fewer patients: Similar results, but inconsistent effect on mortality.2-6
- Quality of life: No clinically important differences.7-9
- Limitations: No direct comparisons of SBP <120 versus <130. Differences in achieved SBP between RCTs with SBP target <120 (intensive 121 versus standard 135) versus target <130 (intensive 131 versus standard 146).
- Accurate SBP measurements are critical to avoid harm with intensive targets.
- SPRINT trial: Optimal blood pressure measurement technique in clinic led to reported SBP ~7 mmHg lower than typical technique (121 versus 128 mmHg).10
- Measurement technique tips available.11
- Canadian11 and international12,13 hypertension guidelines:
- Start medications at BP ≥140/90 mmHg (or ≥130/80 mmHg with cardiovascular disease or 10-year risk ≥20%);
- Target SBP target <130 mmHg for all patients, if tolerated without bothersome side-effects.
- In one study,1 patients valued cardiovascular events three times more than side-effects, but for some patients side effect concerns may outweigh potential benefits.








Interesting
synergistic effects
effects of gabapentin
Good information, it improves risk assessment
reinforces my practice
How about diastolic BP?
What is the target for diastolic BP